Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.12.007Source: DataRank Database

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes is a research paper published in Clinical Breast Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

15 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.65)OA: closedTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Neha Mangini ORCID,John H. Fetting,Deborah K. Armstrong ORCID,Isaac S. Chan ORCID,Roisín M. Connolly ORCID

Live enrichment

PubMed:35074264 OpenAlex:https://openalex.org/W4200611978

Health Research Board

Grant: CTIC-2021-002

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

National Cancer Institute

FWCI

0.65

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S152682092100358X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S152682092100358X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clbc.2021.12.007

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35074264

Fields of Study

PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsBreast NeoplasmsDNA DamageFemaleHumansMutationPhthalazinesPiperazinesRetrospective StudiesBRCA1 ProteinBRCA2 Protein

Keywords

OlaparibMedicineBreast cancerPARP inhibitorGermline mutationOncologyInternal medicineGermlineCancer researchCancerMutationPoly ADP ribose polymeraseGeneticsGeneBiologyPolymeraseParp InhibitorsSomatic Brca1/2

Sustainable Development Goals

SDG 0: Good health and well-being